Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ICER Atopic Dermatitis Review Prompted By First Biologic

Executive Summary

The Institute for Clinical and Economic Review’s assessment of emerging therapies for atopic dermatitis was driven by both excitement and concern from physicians and payers over the anticipated launch of Regeneron/Sanofi’s dupilumab.

Advertisement

Related Content

Sanofi/Regeneron Choose Access Over Price With Dupixent Launch
ICER Eyes QALY Ratios, Budget Impacts In Methods Review

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097516

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel